Premium
Molecular Partners AG (MOLN)
NASDAQ
Hot Features
Inscrivez-vous gratuitement pour obtenir des cotations en temps réel, des graphiques interactifs, un flux d'options en direct et plus encore.
Molecular Partners AG, a clinical-stage biotechnology company, designs and develops designed ankyrin repeat proteins therapeutics for the treatment of oncology diseases in Switzerland. Its product pipeline comprises MP0317, which is in Phase 2 clinical trial for the treatment of advanced solid tumor... Molecular Partners AG, a clinical-stage biotechnology company, designs and develops designed ankyrin repeat proteins therapeutics for the treatment of oncology diseases in Switzerland. Its product pipeline comprises MP0317, which is in Phase 2 clinical trial for the treatment of advanced solid tumors; MP053, novel tetra-specific T cell-engaging DARPin, which is phase 1 clinical trial for the treatment of acute myeloid leukemia; and MP0712, a 212Pb Radio-DARPin therapy (RDT) candidate targeting the tumor-associated protein delta-like ligand 3 (DLL3) which is in Phase 1 clinical trial to treat SCLC and neuroendocrine tumors. It also researches for Switch-DARPin T cell engager to treat CD3 x costim x; and MP0726, a Radio-DARPin Therapy to treat ovarian cancer and other MSLNexpressing cancers. In addition, the company develops MP0621, a Switch-DARPin candidate targeting CD16a, c-KIT, and CD47 as conditioning for hematopoietic stem cell transplantation; and Radio-DARPin Therapy (RDT) platform, a delivery system for effective and selective delivery of radioactive payloads to solid tumors. It has collaboration agreement with Orano Med SAS to develop novel Radio-DARPin therapeutics and an additional six targeted alpha therapeutics candidates and Eckert & Ziegler SE to develop Radio-DARPin therapeutics. Molecular Partners AG was incorporated in 2004 and is headquartered in Schlieren, Switzerland. Show more
| Période | Variation | Variation % | Ouver. | Haut | Bas | Moyenne Vol. Quot. | VWAP | |
|---|---|---|---|---|---|---|---|---|
| 1 | 0.17 | 4.40414507772 | 3.86 | 4.1745 | 3.77 | 15499 | 3.97121199 | DR |
| 4 | 0.13 | 3.33333333333 | 3.9 | 4.1745 | 3.67 | 9882 | 3.8985679 | DR |
| 12 | -0.3 | -6.92840646651 | 4.33 | 4.62 | 3.66 | 6547 | 3.97504629 | DR |
| 26 | -0.3 | -6.92840646651 | 4.33 | 5.36 | 3.66 | 5318 | 4.13133911 | DR |
| 52 | 0.27 | 7.18085106383 | 3.76 | 5.36 | 3.4101 | 4692 | 4.08111924 | DR |
| 156 | -2.3 | -36.3349131122 | 6.33 | 12.7 | 3.32 | 10099 | 5.66231564 | DR |
| 260 | -16.06 | -79.9402687904 | 20.09 | 32.04 | 3.32 | 13554 | 11.60807204 | DR |
Transactions différées
Pour obtenir des transactions en temps réel, améliorez votre compte
Passer à la version en temps réel| Aucune Discussion Trouvée |
| Ajouter une Discussion |
Les dernières valeurs consultées apparaîtront dans cette boîte, vous permettant de choisir facilement les titres vus auparavant.
Assistance: support@advfn.fr
En accédant aux services disponibles de ADVFN, vous acceptez les Conditions Générales de ADVFN Conditions Générales
S'inscrire avec l'e-mail
Vous avez déjà un compte? Connexion
Vous n'avez pas de compte ? Inscription
En m'inscrivant, je confirme avoir lu, compris et accepté les Conditions générales d'ADVFN et j'affirme etre un investisseur privé.
